4. de Botton S, Yee KW, Wei A, et al. Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): results from a planned interim analysis of a phase 2 clinical ...
在我们前期开展的工作中(Blood. 2018;132, Supplement 1:2813),通过对23例复发成人CN-AML患者初诊、缓解及复发时期三重配对的骨髓DNA样本进行全外显子组测序,筛选出多个潜在的AML复发相关基因,其中包括鲜见报道的DDX11基因突变(图1)。DDX11基因编码一种铁硫簇DNA解旋酶,促进染色质结构的维持和DNA的修复,在维持基...
[2] Joseph DK,Eric S,Oussama A,et al.The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.Leukemia.2022 Jul;36(7):1703-1719. [3]Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of...
第一/通讯发表SCI 论文122篇Nat. Immunol, J Hematol Oncol, Lancet Heamatol, Blood, Nat. Commun, Am J Hematol, Leukemia,等 获“国之名医·卓越建树”称号 以第一完成人获:华夏医学科技奖一等奖;中华医学科技奖二等奖 以共同完...
Optimal blood sampling for detecting acute myelogenous leukemia (AML) relapseAn approach to select optimal blood sampling schedules for AML patients could help improve detection of relapse and evaluation of therapies for refractory disease. Further details on the research, next steps and licensing status...
近日,哈佛大学医学院/丹娜法伯癌症研究所赵景 (Jean J. Zhao)教授团队在Blood杂志在线发表了题为PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway的研究性论文,揭示PI3Kγ通过激活AKT信号增强NRF2入核转录调控PGD的表达,以此促进磷酸戊糖途径和核酸...
This approach relies on modifying T cells isolated from the peripheral blood of AML patients, which presents challenges in achieving the comparable response rates observed in B-cell acute lymphoblastic leukemia (B-ALL). The activated CAR-T secreted cytokines like GM-CSF, FLT3L and IL-3 will ...
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by an accumulation of immature cells of the myeloid lineage. Although most patients initially respond to chemotherapy, ∼75% relapse and succumb to the disease within 5 years of diagnosis. Efforts to link AML relapse to gen...
, the results are nevertheless consistent with our prior work showing that LIN28B impedes MLL::ENL-driven AML initiation by stabilizing MYBBP1A expression [11]. Future studies should investigate whether leukemia-suppressive effects of LIN28B extend to other drivers of pediatric AML. Furthermore, ...
infusion in acute myeloid leukemia post-allogeneic stem cell transplant, second, phase I/II (NCT05155709) a study of siremadlin in combination with venetoclax plus azacitidine in adult participants with acute myeloid leukemia (AML) who are ineligible for chemotherapy. The results remain to be ...